Next Generation Mass Spectrometry-Based Solution Analyzes Dried Blood Spots from Newborn Babies to Test for Wide Range of Metabolic Disorders

WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its NeoBase™ 2 non-derivatized MSMS Kit, which obtained CE mark approval allowing distribution in Europe  . This new in-vitro diagnostic (IVD) kit is intended for the semi-quantitative measurement and evaluation of amino acid, succinylacetone, free carnitine, acylcarnitine, nucleoside and lysophospholipid concentrations.  The kit analyzes newborn heel prick blood samples dried on filter paper and is used with a tandem mass spectrometer.

HOW IT WORKS: The NeoBase2 MSMS kit can test for up to 57 analytes, including markers for screening of X-linked adrenoleukodystrophy (X-ALD), the most common peroxisomal disorder.  It can also screen for adenosine deaminase severe combined immunodeficiency (ADA-SCID), which is caused by a deficiency of the enzyme ADA and is the second most common SCID.

The NeoBase2 MSMS kit enables labs to use a simple three-step assay workflow to screen for more disorders in less time from a single dried blood spot punch.  PerkinElmer’s optional MSMS Workstation software, which includes database functionality, helps labs effectively store, manage, review and report results.

WHY: “As the industry leader in mass spectrometry-based newborn screening, we continue to evolve our technologies to meet the needs of laboratories worldwide, especially as more countries mandate certain metabolic tests such as those for SCIDs and peroxisomal disorders,” said Linh Hoang MD, PhD, Vice President, Neonatal Screening, PerkinElmer.  “As these labs face pressure to screen for more disorders in less time and with limited resources, they are seeking advanced technology to expand their MSMS testing capabilities.”

MORE: PerkinElmer currently serves customers in more than 100 countries worldwide.  Its customers have screened more than 600 million babies throughout the world for life- threatening diseases: screening 39 million babies annually around the world, helping to save more than 70 babies per day (one baby every 20 minutes).

For additional information on PerkinElmer’s NeoBase 2 MSMS kit, please click here.

ABOUT PERKINELMER:         

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world.  Our dedicated team of more than 11,000 employees worldwide is passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com